Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial

S Golan, M Frumer, Y Zohar, E Rosenbaum… - European Urology …, 2023 - Elsevier
Background High-risk localized prostate cancer (HRLPC) has a substantial risk of disease
progression despite local treatment. Neoadjuvant systemic therapy before definitive local …
被引用次数：21 相关文章

Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial

S Golan, M Frumer, Y Zohar… - European …, 2023 - euoncology.europeanurology.com
Background High-risk localized prostate cancer (HRLPC) has a substantial risk of disease
progression despite local treatment. Neoadjuvant systemic therapy before definitive local …

Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial

S Golan, M Frumer, Y Zohar… - European urology …, 2023 - pubmed.ncbi.nlm.nih.gov
Background High-risk localized prostate cancer (HRLPC) has a substantial risk of disease
progression despite local treatment. Neoadjuvant systemic therapy before definitive local …

Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial.

S Golan, M Frumer, Y Zohar, E Rosenbaum… - European Urology …, 2022 - europepmc.org
Background High-risk localized prostate cancer (HRLPC) has a substantial risk of disease
progression despite local treatment. Neoadjuvant systemic therapy before definitive local …